T-DXd plus radiation for HER2-positive breast cancer brain tumors
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests a combination of a targeted drug (T-DXd) and precise radiation (stereotactic radiotherapy) for people with HER2-positive breast cancer that has spread to the brain. The goal is to see if this approach can better control brain tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer that has spread to the brain (confirmed by MRI).
- You have fewer than 15 brain tumors.
- You are in fairly good health (able to do most daily activities).
- Your kidney, liver, and blood cell counts meet certain safety levels.
- You haven't had any other cancer treatment in the last 2 weeks, and side effects are mild.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
This trial tests a new way of giving the targeted drug T-DXd—directly into the fluid around your spine (intrathecal) or through a device under your scalp called an Ommaya reservoir. It's designed for people with HER2-positive breast cancer that has spread to the brain or the lining of the brain/spinal cord.
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
This trial tests a combination of a targeted drug (Enhertu) with precise radiation (SRS) for people whose HER2-positive breast cancer has spread to the brain. It aims to see if this combo is safe and effective for treating brain metastases.
This trial tests a combination of two targeted therapies, Trastuzumab Deruxtecan (T-DXd) and Pyrotinib, as a first treatment for HER2-positive breast cancer that has spread or cannot be removed. It aims to see if this combination works better than standard treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.